Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athenex Inc ATNXQ

Healthcare Biotechnology
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is... see more

Recent & Breaking News (GREY:ATNXQ)

Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference

GlobeNewswire May 19, 2020

ATNX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Athenex, Inc. and Encourages Investors to Contact the Firm

ACCESSWIRE IA May 8, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Athenex, Inc. - ATNX

GlobeNewswire May 7, 2020

Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 7, 2020

Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program

GlobeNewswire April 29, 2020

Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020

GlobeNewswire April 23, 2020

Athenex Provides an Update on Oral Paclitaxel FDA Meeting

GlobeNewswire April 9, 2020

Athenex Provides a Corporate Update

GlobeNewswire March 13, 2020

Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis

GlobeNewswire March 9, 2020

Athenex's Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis

GlobeNewswire March 2, 2020

Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update

GlobeNewswire February 27, 2020

Athenex Announces Participation at the Cowen 40th Annual Health Care Conference

GlobeNewswire February 25, 2020

Athenex, Inc. to Report Fourth Quarter and Full Year 2019 Earnings Results on February 27, 2020

GlobeNewswire February 6, 2020

Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma

GlobeNewswire February 3, 2020

Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

GlobeNewswire December 16, 2019

Faruqi & Faruqi, LLP is Investigating Athenex, Inc. (ATNX) on Behalf of its Shareholders

PR Newswire December 13, 2019

Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer

GlobeNewswire December 13, 2019

Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019

GlobeNewswire December 11, 2019

Athenex Announces $60 Million Private Placement

GlobeNewswire December 5, 2019

Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium

GlobeNewswire November 19, 2019